Saturday, October 31, 2026

Intel Stock Tumbles Following Reports of Stricter Export Controls to China

Intel's stock fell over 5% due to potential new semiconductor export controls to China, raising concerns about revenue loss.

North Korea’s Military Breach: What You Need to Know About MDL Violations in 2026

Military mines have been set up beyond the Military Demarcation Line by North Korean forces in various frontline areas.

Kim Jong Un, Makes ‘Important Decision’ Regarding ‘9th Party Congress’… Mourns Deceased Russian Ambassador [Daily North Korea]

North Korea prepares for the 9th Congress of the Workers' Party, with Kim Jong Un issuing key directives and evaluating past policies.

News1

Author's Latest

Discover Why Dermagram PDRN Cream is the Must-Have K-Beauty Product for Foreign Tourists in Korea

Chong Kun Dang's PDRN cream is recommended for foreign tourists on Korea Tourism Organization's official portal.

Robot-Assisted Surgery Removes Uterine Fibroids Up to 11 Centimeters While Preserving Fertility

A surgeon at Soonchunhyang University Bucheon Hospital used robot-assisted surgery to remove large, multiple uterine fibroids from three women in their 30s and 40s who planned to become pregnant, preserving their uteruses.

Dong-A ST Sees Potential for Topical Formulation of Psoriasis Drug Icotrokinra

Dong-A ST reported preclinical findings suggesting that icotrokinra, an oral treatment for psoriasis, could be developed into a topical formulation that delivers the drug through the skin and reduces inflammation.

Samsung Bioepis Confirms Pharmacokinetic Equivalence in Phase 1 Trial of Keytruda Biosimilar

Samsung Bioepis reported that its Keytruda biosimilar candidate SB27 demonstrated pharmacokinetic equivalence to the original drug in a Phase 1 trial, supporting its continued development as a potential lower-cost immunotherapy for cancer patients.

Hanmi Pharmaceutical’s Weight-Loss Drug Epe Expected to Become Available for Prescriptions on Oct. 29

Hanmi Pharmaceutical’s obesity treatment Epe is expected to become available at some medical institutions on Oct. 29, with its relatively low initial supply price potentially improving access as nationwide distribution ramps up.

Ilsan CHA Hospital Reaches 20,000 Deliveries, With High-Risk Births Accounting for More Than Half

Ilsan CHA Hospital has recorded 20,000 deliveries since opening its maternity services in January 2020, with more than half involving high-risk pregnancies, highlighting its role in providing specialized maternal and newborn care in northern Gyeonggi Province.

XERF: The Revolutionary High-Frequency Medical Device Expanding in Europe and North America

Cynosure Lutronic is expanding the global market for its high-frequency medical device XERF through conferences for healthcare professionals.

Unlocking the U.S. Market: How South Korean Medical Device Companies Can Succeed with STAMPED Program

The Korea Health Industry Development Institute partners with Texas Medical Center to support domestic health companies entering the U.S. market.

Revolutionary Gene Therapy for Gitelman Syndrome: How Korean Researchers are Restoring Kidney Function

Researchers confirmed that inserting normal genes into cells of patients with Gitelman syndrome restores sodium transport function.

Revolutionary Antiviral Jepti Unveiled at IDWeek 2026: What It Means for Dengue and Similar Viruses

Hyundai BioScience's antiviral candidate Jepti (CP-COV03) was presented at the major U.S. infectious disease conference IDWeek 2026.

SillaJen’s BAL0891: A Breakthrough in Cancer Treatment Revealed at ESMO 2026

SillaJen reveals interim results for next-gen cancer drug BAL0891 at ESMO 2026, accelerating its new drug development.

Top Dental Equipment Service: Osstem Implant Dominates A/S Satisfaction Survey

Osstem Implant ranked first in service speed, problem-solving ability, and overall satisfaction in a survey of 1,000 dentists.

2026 ESMO: ABL Bio Unveils Promising Clinical Results for Dual Antibody Cancer Drugs

ABL Bio showcases clinical results of two bispecific antibody immunotherapies at ESMO 2026, accelerating global drug development.

How EuBiologics’ Cholera Vaccine is Driving Profits: Insights for Investors

Ubiologics aims for performance recovery and premium vaccine development in the second half, leveraging stable cholera vaccine profitability.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.